Compare EQX & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQX | PRAX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 9.0B |
| IPO Year | 2018 | 2020 |
| Metric | EQX | PRAX |
|---|---|---|
| Price | $11.51 | $264.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | $17.00 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 9.7M | 378.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $102.84 | N/A |
| Revenue Next Year | $15.55 | $7,758.26 |
| P/E Ratio | $137.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.64 | $37.25 |
| 52 Week High | $18.96 | $366.52 |
| Indicator | EQX | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 33.30 |
| Support Level | $10.28 | $157.29 |
| Resistance Level | $15.44 | $342.62 |
| Average True Range (ATR) | 0.62 | 21.69 |
| MACD | -0.11 | -9.38 |
| Stochastic Oscillator | 10.70 | 9.02 |
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. The company operates gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the Canada, United States, Mexico, and others. The majority of its revenue is generated from Canada.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.